Ignite Creation Date:
2025-12-25 @ 1:18 AM
Ignite Modification Date:
2026-02-20 @ 8:15 PM
Study NCT ID:
NCT06303193
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-24
First Post:
2024-03-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Myelodysplastic Syndromes | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Myelodysplastic Syndrome | View |
| None | bone marrow disorder | View |
| None | Myelodysplasia | View |
| None | myeloproliferative disorders | View |
| None | pediatric bone marrow failure | View |
| None | 5q deletion | View |
| None | multi-lineage dysplasia | View |
| None | Clonal Hematopoiesis | View |
| None | Aplastic Anemia | View |